Literature DB >> 16528712

Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases.

Saiho Ko1, Eiji Okano, Hiromichi Kanehiro, Masanori Matsumoto, Hiromichi Ishizashi, Masahito Uemura, Yoshihiro Fujimura, Koichi Tanaka, Yoshiyuki Nakajima.   

Abstract

A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) is a metalloproteinase that specifically cleaves the multimeric von Willebrand factor (VWF). Deficiency of ADAMTS13 increases the unusually large VWF multimers (UL-VWFM), which leads to platelet clumping and/or thrombus formation, resulting in microcirculatory disturbance. We serially determined the activity of plasma ADAMTS13, together with VWF antigen (VWF:Ag) and UL-VWFM, in association with the development of early graft dysfunction in 3 liver transplant recipients and 4 patients with major hepatectomy as controls. In case 1, ADAMTS13 activity decreased markedly from 108% to less than 3% with concomitant thrombocytopenia on posttransplantation day 7, when acute rejection occurred. Simultaneously, UL-VWFM were detected. During the second episode of rejection, VWF:Ag increased to 368% with the appearance of UL-VWFM, while ADAMTS13 activity was as low as 18%, indicating an imbalance between a large amount of UL-VWFM and low activity of ADAMTS13. Administration of fresh frozen plasma (FFP) together with treatment for acute rejection resulted in an improvement of ADAMTS13 activity and disappearance of the UL-VWFM. In case 2, ADAMTS13 activity promptly decreased to 9% with thrombocytopenia on day 1, when ischemia-reperfusion injury occurred. Subsequently, the ADAMTS13 activity increased steadily without appearance of UL-VWFM, and the patient recovered uneventfully. ADAMTS13 activity decreased to 15% immediately after transplantation in case 3 as well. In contrast, ADAMTS13 activity never decreased below 20% in 4 patients with major hepatectomy as controls. In conclusion, these results indicate that the kinetics of ADAMTS13 and UL-VWFM could be good indicators of adverse events after liver transplantation. Our findings not only suggest a novel mechanism for thrombocytopenia, but also provide a useful tool for diagnosis of graft dysfunction in the early stage after transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528712     DOI: 10.1002/lt.20733

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  8 in total

1.  Dysfunction in Patients With Small-for-Size Grafts After Living Donor Liver Transplantation.

Authors:  Shozo Mori; Min-Su Park; Hyeyoung Kim; Youngrok Choi; Geun Hong; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Int Surg       Date:  2015-03

2.  Recombinant human ADAMTS13 treatment and anti-NET strategies enhance skin allograft survival in mice.

Authors:  Siu Ling Wong; Jeremy Goverman; Caleb Staudinger; Denisa D Wagner
Journal:  Am J Transplant       Date:  2019-12-12       Impact factor: 8.086

Review 3.  Relevance of ADAMTS13 to liver transplantation and surgery.

Authors:  Saiho Ko; Hisanao Chisuwa; Masanori Matsumoto; Yoshihiro Fujimura; Eiji Okano; Yoshiyuki Nakajima
Journal:  World J Hepatol       Date:  2015-07-08

4.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

Review 5.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

6.  Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of splenectomy: the significance of ADAMTS13 and graft function [corrected].

Authors:  Yu Nobuoka; Hideo Wada; Shugo Mizuno; Masashi Kishiwada; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata; Toshihiko Kobayashi; Tsutomu Nobori; Shinji Uemoto; Shuji Isaji
Journal:  Int J Hematol       Date:  2014-03-05       Impact factor: 2.490

7.  Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hepatol       Date:  2011-07-18

8.  Evidence for a rebalanced hemostatic system in pediatric liver transplantation: A prospective cohort study.

Authors:  Maureen J M Werner; Vincent E de Meijer; Jelle Adelmeijer; Ruben H J de Kleine; René Scheenstra; Sander T H Bontemps; Koen M E M Reyntjens; Jan B F Hulscher; Ton Lisman; Robert J Porte
Journal:  Am J Transplant       Date:  2020-01-08       Impact factor: 8.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.